Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 5:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 2,158 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atherosclerosis, Coronary Clear all
Terminated Phase 2 Interventional Results available

SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy

NCT03606642
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Stent Placement
Interventions
Dual Antiplatelet (DAPT) Therapy, The Synergy® stent
Drug · Device
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
75 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 13, 2026, 5:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Trial Comparison of Accuseal and Bovine Pericardial Patch During Endarterectomy

NCT01184183
View directory record Official record
Conditions
Coronary Stenosis
Interventions
Comparing Accuseal Vs. Bovine Pericardial in CEA
Procedure
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 13, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

Cangrelor Ticagrelor Transition Study

NCT01766466
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
cangrelor, Ticagrelor
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 13, 2026, 5:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Determinants of Cardiac Risk Factor Modification in Latinos With Coronary Artery Disease

NCT00248859
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2017 · Synced Oct 13, 2026, 5:29 PM EDT
Recruiting No phase listed Observational

Cardiogenic Shock Working Group Registry

NCT04682483
View directory record Official record
Conditions
Cardiogenic Shock
Interventions
Vasopressor, Inotrope, Acute Mechanical Circulatory Support Devices
Drug · Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
16
States / cities
Weston, Florida • Chicago, Illinois • Portland, Maine + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 13, 2026, 5:29 PM EDT
Completed Phase 4 Interventional

Study of the SafeSeal(TM) Hemostasis Patch Following Percutaneous Coronary Artery and Peripheral Vascular Interventions

NCT00481741
View directory record Official record
Conditions
Coronary Artery Disease, Peripheral Vascular Disease
Interventions
SafeSeal(TM) Hemostasis Patch
Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2009 · Synced Oct 13, 2026, 5:29 PM EDT
Completed No phase listed Observational Results available

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study

NCT01249027
View directory record Official record
Conditions
Angioplasty, Chronic Coronary Occlusion, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
2,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 13, 2026, 5:29 PM EDT
Completed Phase 3 Interventional

Higher-Dose Ezetimibe to Treat Homozygous Sitosterolemia

NCT00099996
View directory record Official record
Conditions
Heart Diseases, Metabolism, Inborn Errors
Interventions
SCH-58235, Ezetimibe
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 13, 2026, 5:29 PM EDT
Active, not recruiting Not applicable Interventional

Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial

NCT03108456
View directory record Official record
Conditions
Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction
Interventions
Orbital Atherectomy, Balloon
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
104
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 13, 2026, 5:29 PM EDT
Not listed No phase listed Observational

OCT and Scaffold Embedding After NC Balloon

NCT03106961
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Bioresorbable vascular scaffolds, OCT, non-compliant ballooning
Device
Lead sponsor
St. Francis Hospital, New York
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Roslyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 13, 2026, 5:29 PM EDT
Completed Not applicable Interventional

Effect of Exercise on Elevated C-reactive Protein Concentrations in Formerly Inactive Adults

NCT00113061
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Obesity
Interventions
Exercise
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Oct 13, 2026, 5:29 PM EDT
Completed Not applicable Interventional

Women's Heart Attack Research Program: Stress Ancillary Study

NCT02914483
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Enhanced Usual Care, Stress Management, Actigraph
Behavioral · Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 99 Years · Female only
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
12
States / cities
Los Angeles, California • Gainesville, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 13, 2026, 5:29 PM EDT
Not listed Phase 2 Interventional

RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease

NCT00385385
View directory record Official record
Conditions
Coronary Artery Disease, Cerebrovascular Disease, Peripheral Vascular Disease
Interventions
Rifalazil
Drug
Lead sponsor
ActivBiotics
Industry
Eligibility
50 Years to 85 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Lansing, Michigan • Roslyn, New York • Stony Brook, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2007 · Synced Oct 13, 2026, 5:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Training Intensity on the CHD Risk Factors in Postmenopausal Women

NCT00000108
View directory record Official record
Conditions
Cardiovascular Diseases, Coronary Disease
Interventions
Exercise
Behavioral
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
50 Years to 65 Years · Female only
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 13, 2026, 5:29 PM EDT
Completed No phase listed Observational

RESOLUTE ONYX Post-Approval Study

NCT03063749
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
23
States / cities
Huntsville, Alabama • La Jolla, California • Riverside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 13, 2026, 5:29 PM EDT
Not listed Not applicable Interventional

Functional Lesion Assessment of Intermediate Stenosis to Guide Revascularisation

NCT02053038
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
iFR, FFR
Device
Lead sponsor
Imperial College London
Other
Eligibility
18 Years to 90 Years
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
6
States / cities
Long Beach, California • Lakewood, Colorado • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 13, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

Effect of Beetroot Juice on Coronary Blood Flow and Walking Performance in PAD

NCT02553733
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Beetroot juice, Beetroot juice placebo
Drug
Lead sponsor
David N. Proctor, PhD
Other
Eligibility
21 Years to 85 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 13, 2026, 5:29 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Smartphone Application to PREDICT Real-Time Cardiovascular Risk for Heart Attack and Stroke

NCT07735338
View directory record Official record
Conditions
Myocardial Infarction (MI), Stroke
Interventions
Smartphone application Antshrike
Device
Lead sponsor
Stanford University
Other
Eligibility
40 Years to 79 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 13, 2026, 5:29 PM EDT
Terminated Phase 2 Interventional

Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease

NCT00137332
View directory record Official record
Conditions
Arrhythmia
Interventions
GAP-486 (ZP-123), 0.9% Sodium Chloride, USP
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
19
States / cities
Sacramento, California • San Francisco, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2007 · Synced Oct 13, 2026, 5:29 PM EDT
Recruiting Not applicable Interventional

Examination of the Impact of CalmiGo's Stress Management Device on Vascular Heath and Cardiovascular Disease Risk.

NCT04521699
View directory record Official record
Conditions
Myocardial Infarction
Interventions
CalmioGO Stress management device
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 13, 2026, 5:29 PM EDT
Terminated No phase listed Observational

CorPath GRX STEMI Study

NCT04459299
View directory record Official record
Conditions
STEMI - ST Elevation Myocardial Infarction, CAD
Interventions
Robotic-PCI (CorPath GRX System)
Device
Lead sponsor
Siemens Healthineers Endovascular Robotics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 13, 2026, 5:29 PM EDT
Not listed Phase 4 Interventional

Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome

NCT01170338
View directory record Official record
Conditions
Smoking, Acute Coronary Syndrome
Interventions
Varenicline 100 mg by mouth twice daily, control
Drug
Lead sponsor
Newark Beth Israel Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 27, 2010 · Synced Oct 13, 2026, 5:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Examining the Long-Term Risks of Oophorectomy

NCT00655447
View directory record Official record
Conditions
Coronary Heart Disease, Stroke, Breast Cancer, Ovarian Cancer, Cancer, Hip Fracture, Death
Interventions
Not listed
Lead sponsor
Parker, William H., M.D.
Other
Eligibility
30 Years to 55 Years · Female only
Enrollment
32,175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1980 – 2004
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2008 · Synced Oct 13, 2026, 5:29 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable

NCT06763549
View directory record Official record
Conditions
Cardiopulmonary Failure, Myocardial Infarction (MI), Heart Decompensation, Heart Failure, HFrEF - Heart Failure with Reduced Ejection Fraction, HFpEF - Heart Failure with Preserved Ejection Fraction, Syncopation, Syncope, Ischemic Cardiovascular Disease, STEMI, STEMI (ST Elevation MI), Atrial Fibrillation (AF), Atrial Enlargement, LVF, Conduction Defect, Conduction Abnormalities, Heart Block, Valvular Diseases, Cardiac Output, Low, Stroke Volume, Stroke Volume Variation, Hyperkalemia, Hypercalcemia, Hypocalcemia, LV Dysfunction, QT Prolongation, Sudden Cardiac Death Due to Cardiac Arrhythmia, Ventricular Arrhythmia, Pacing, Pacing Induced Dyssynchrony, Silent Ischemia, Pericarditis, Sleep Related Breathing Disorder, RSA, Apnea, Obstructive, Cardiac Output Measurement, Respiratory Impedance, CRT And/or ICD, Infarction, Cardiomyopathies, Primary, Hypertrophy
Interventions
SUBPROTOCOL A, SUBPROTOCOL B, SUBPROTOCOL C, SUBPROTOCOL D, SUBPROTOCOL E, SUBPROTOCOL F, SUBPROTOCOL G, SUBPROTOCOL H
Device
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
15,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 13, 2026, 5:29 PM EDT